<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37814219</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2730-6844</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC genomic data</Title><ISOAbbreviation>BMC Genom Data</ISOAbbreviation></Journal><ArticleTitle>Correlation study of malignant lymphoma and breast Cancer in different gender European populations: mendelian randomization analysis.</ArticleTitle><Pagination><StartPage>59</StartPage><MedlinePgn>59</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">59</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12863-023-01162-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous research has already indicated an elevated risk of breast cancer (BC) among survivors of malignant lymphoma, but the underlying reasons remain unknown. Our objective is to elucidate the causal relationship between malignant lymphoma and BC through Mendelian randomization (MR). Genome-wide association studies (GWAS) data from 181,125 Hodgkin lymphoma (HL) patients and 181,289 non-Hodgkin lymphoma (NHL) patients from the FinnGen Consortium were utilized as exposure. We selected single nucleotide polymorphisms (SNPs) strongly associated with the exposure as instrumental variables to investigate their relationship with BC in a cohort of 107,722 participants. Subsequently, we obtained data from the UK Biobank containing gender-stratified information on HL, NHL, and BC. We validated the findings from our analysis and explored the impact of gender. The Inverse-Variance Weighted (IVW) method served as the primary reference for the two-sample MR, accompanied by tests for heterogeneity and pleiotropy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The analysis results from the FinnGen consortium indicate that there is no causal relationship between HL and NHL with BC. HL (OR&#x2009;=&#x2009;1.01, 95% CI&#x2009;=&#x2009;0.98-1.04, p&#x2009;=&#x2009;0.29), NHL (OR&#x2009;=&#x2009;1.01, 95% CI&#x2009;=&#x2009;0.96-1.05, p&#x2009;=&#x2009;0.64). When utilizing GWAS data from the UK Biobank that includes different gender cohorts, the lack of association between HL, NHL, and BC remains consistent. HL (OR&#x2009;=&#x2009;1.08, 95% CI&#x2009;=&#x2009;0.74-1.56, p&#x2009;=&#x2009;0.69), HL-Female (OR&#x2009;=&#x2009;0.84, 95% CI&#x2009;=&#x2009;0.59-1.19, p&#x2009;=&#x2009;0.33), NHL (OR&#x2009;=&#x2009;0.89, 95% CI&#x2009;=&#x2009;0.66-1.19, p&#x2009;=&#x2009;0.44), and NHL-Female (OR&#x2009;=&#x2009;0.81, 95% CI&#x2009;=&#x2009;0.58-1.11, p&#x2009;=&#x2009;0.18).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The two-sample MR analysis indicates that there is no significant causal relationship between malignant lymphoma (HL and NHL) and BC. The association between malignant lymphoma and breast cancer requires further in-depth research and exploration.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Changsha Hospital of Hunan Normal University, Changsha, 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>GuoHuang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Changsha Hospital of Hunan Normal University, Changsha, 410000, China. huguohuanghnnu@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>grant no. kq2004154</GrantID><Agency>Changsha Natural Science Foundation</Agency><Country/></Grant><Grant><GrantID>grant no. kq2004154</GrantID><Agency>Changsha Natural Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Genom Data</MedlineTA><NlmUniqueID>101775394</NlmUniqueID><ISSNLinking>2730-6844</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">Hodgkin disease</Keyword><Keyword MajorTopicYN="N">Malignant lymphoma</Keyword><Keyword MajorTopicYN="N">Mendelian randomization</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37814219</ArticleId><ArticleId IdType="doi">10.1186/s12863-023-01162-1</ArticleId><ArticleId IdType="pii">10.1186/s12863-023-01162-1</ArticleId><ArticleId IdType="pmc">PMC10561426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409&#x2013;18. doi: 10.3322/caac.20134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20134</ArticleId><ArticleId IdType="pubmed">21969133</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. doi: 10.1038/s41572-019-0111-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0111-2</ArticleId><ArticleId IdType="pubmed">31548545</ArticleId></ArticleIdList></Reference><Reference><Citation>Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. 2001;286:2143&#x2013;51. doi: 10.1001/jama.286.17.2143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.17.2143</ArticleId><ArticleId IdType="pubmed">11694156</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigelson HS, Bodelon C, Powers JD, et al. Body Mass Index and Risk of Second Cancer among women with breast Cancer. J Natl Cancer Inst. 2021;113:1156&#x2013;60. doi: 10.1093/jnci/djab053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djab053</ArticleId><ArticleId IdType="pmc">PMC8757319</ArticleId><ArticleId IdType="pubmed">33823007</ArticleId></ArticleIdList></Reference><Reference><Citation>Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a mendelian randomisation study. BMC Med. 2020;18:327. doi: 10.1186/s12916-020-01797-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01797-2</ArticleId><ArticleId IdType="pmc">PMC7670589</ArticleId><ArticleId IdType="pubmed">33198768</ArticleId></ArticleIdList></Reference><Reference><Citation>Opstal-van Winden AWJ, de Haan HG, Hauptmann M, et al. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood. 2019;133:1130&#x2013;9. doi: 10.1182/blood-2018-07-862607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-07-862607</ArticleId><ArticleId IdType="pmc">PMC6405334</ArticleId><ArticleId IdType="pubmed">30573632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma YP, van Leeuwen FE, Cooke R, et al. FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood. 2012;119:1029&#x2013;31. doi: 10.1182/blood-2011-10-383380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-10-383380</ArticleId><ArticleId IdType="pubmed">22144180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin&#x2019;s disease. N Engl J Med. 1996;334:745&#x2013;51. doi: 10.1056/NEJM199603213341201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199603213341201</ArticleId><ArticleId IdType="pubmed">8592547</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217&#x2013;23. doi: 10.1200/JCO.2013.54.4601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.54.4601</ArticleId><ArticleId IdType="pmc">PMC4100937</ArticleId><ArticleId IdType="pubmed">24752044</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin&#x2019;s lymphoma in England and Wales: a National Cohort Study. J Clin Oncol. 2012;30:2745&#x2013;52. doi: 10.1200/JCO.2011.38.8835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.8835</ArticleId><ArticleId IdType="pubmed">22734026</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin&#x2019;s disease. Cancer. 1997;79:1203&#x2013;10. doi: 10.1002/(sici)1097-0142(19970315)79:6&lt;1203::aid-cncr20&gt;3.0.co;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0142(19970315)79:6&lt;1203::aid-cncr20&gt;3.0.co;2-2</ArticleId><ArticleId IdType="pubmed">9070499</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second Cancer Risk up to 40 years after treatment for Hodgkin&#x2019;s lymphoma. N Engl J Med. 2015;373:2499&#x2013;511. doi: 10.1056/NEJMoa1505949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505949</ArticleId><ArticleId IdType="pubmed">26699166</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberti S, van Leeuwen FE, Ronckers CM, et al. Radiotherapy-Related dose and irradiated volume Effects on breast Cancer risk among Hodgkin Lymphoma Survivors. J Natl Cancer Inst. 2022;114:1270&#x2013;8. doi: 10.1093/jnci/djac125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djac125</ArticleId><ArticleId IdType="pmc">PMC9468297</ArticleId><ArticleId IdType="pubmed">35771630</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465&#x2013;75. doi: 10.1001/jama.290.4.465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.290.4.465</ArticleId><ArticleId IdType="pubmed">12876089</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump M, Hodgson D. Secondary breast cancer in Hodgkin&#x2019;s lymphoma survivors. J Clin Oncol. 2009;27:4229&#x2013;31. doi: 10.1200/JCO.2009.22.9120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.22.9120</ArticleId><ArticleId IdType="pubmed">19667263</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries S, Krul I, Schaapveld M, et al. Risk of male breast cancer after Hodgkin lymphoma. Blood Blood. 2023;2023020940. 10.1182/blood.2023020940.</Citation><ArticleIdList><ArticleId IdType="pubmed">37390297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D, Yoon SE, Shin D, et al. Risk of non-hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer J. 2021;11:200. doi: 10.1038/s41408-021-00595-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00595-0</ArticleId><ArticleId IdType="pmc">PMC8671407</ArticleId><ArticleId IdType="pubmed">34907177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccali C, Testa A, Spoto B, et al. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis. 2006;47:332&#x2013;41. doi: 10.1053/j.ajkd.2005.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.10.027</ArticleId><ArticleId IdType="pubmed">16431263</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S. Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1&#x2013;22. doi: 10.1093/ije/dyg070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyg070</ArticleId><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Holmes MV. Meta-analysis and mendelian randomization: a review. Res Synth Methods. 2019;10:486&#x2013;96. doi: 10.1002/jrsm.1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1346</ArticleId><ArticleId IdType="pmc">PMC6973275</ArticleId><ArticleId IdType="pubmed">30861319</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NM, Holmes MV, Davey Smith G. Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. doi: 10.1136/bmj.k601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k601</ArticleId><ArticleId IdType="pmc">PMC6041728</ArticleId><ArticleId IdType="pubmed">30002074</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekula P, Del Greco MF, Pattaro C, K&#xf6;ttgen A. Mendelian randomization as an Approach to assess causality using Observational Data. J Am Soc Nephrol. 2016;27:3253&#x2013;65. doi: 10.1681/ASN.2016010098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016010098</ArticleId><ArticleId IdType="pmc">PMC5084898</ArticleId><ArticleId IdType="pubmed">27486138</ArticleId></ArticleIdList></Reference><Reference><Citation>Boef AGC, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44:496&#x2013;511. doi: 10.1093/ije/dyv071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv071</ArticleId><ArticleId IdType="pubmed">25953784</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465&#x2013;78. doi: 10.1007/s10654-021-00757-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-021-00757-1</ArticleId><ArticleId IdType="pmc">PMC8159796</ArticleId><ArticleId IdType="pubmed">33961203</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693&#x2013;8. doi: 10.1038/s41588-018-0099-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton RE, Lawn RB, Millard LAC, et al. Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: mendelian randomisation study. BMJ. 2018;362:k3788. doi: 10.1136/bmj.k3788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k3788</ArticleId><ArticleId IdType="pmc">PMC6155050</ArticleId><ArticleId IdType="pubmed">30254091</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40:740&#x2013;52. doi: 10.1093/ije/dyq151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyq151</ArticleId><ArticleId IdType="pmc">PMC3147064</ArticleId><ArticleId IdType="pubmed">20813862</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;60. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512&#x2013;25. doi: 10.1093/ije/dyv080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv080</ArticleId><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AE, Schilder BM, Skene NG. MungeSumstats: a Bioconductor package for the standardization and quality control of many GWAS summary statistics. Bioinformatics. 2021;37:4593&#x2013;6. doi: 10.1093/bioinformatics/btab665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab665</ArticleId><ArticleId IdType="pmc">PMC8652100</ArticleId><ArticleId IdType="pubmed">34601555</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin&#x2019;s disease. J Clin Oncol. 2003;21:3431&#x2013;9. doi: 10.1200/JCO.2003.07.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2003.07.131</ArticleId><ArticleId IdType="pubmed">12885835</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428&#x2013;37. doi: 10.1093/jnci/dji290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dji290</ArticleId><ArticleId IdType="pubmed">16204692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin&#x2019;s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484&#x2013;94. doi: 10.1200/JCO.2002.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2002.09.038</ArticleId><ArticleId IdType="pubmed">12177110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin&#x2019;s disease and non-hodgkin&#x2019;s lymphoma survivors. Ann Oncol. 2007;18:288&#x2013;92. doi: 10.1093/annonc/mdl399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdl399</ArticleId><ArticleId IdType="pubmed">17088328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X, Yue P, Zhou F. Risk and prognosis of secondary breast cancer after radiation therapy for non-hodgkin lymphoma: a massive population-based analysis. Clin Transl Oncol. 2023;25:1307&#x2013;14. doi: 10.1007/s12094-022-03026-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-022-03026-z</ArticleId><ArticleId IdType="pubmed">36478146</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry-Amar M, Joly F. Late complications after Hodgkin&#x2019;s disease. Ann Oncol 7 Suppl. 1996;4:115&#x2013;26. doi: 10.1093/annonc/7.suppl_4.s115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/7.suppl_4.s115</ArticleId><ArticleId IdType="pubmed">8836422</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113:3679&#x2013;81. doi: 10.1182/blood-2008-10-184705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-10-184705</ArticleId><ArticleId IdType="pubmed">19234144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dores GM, Curtis RE, van Leeuwen FE, et al. Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol. 2014;25:2073&#x2013;9. doi: 10.1093/annonc/mdu287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdu287</ArticleId><ArticleId IdType="pmc">PMC4176454</ArticleId><ArticleId IdType="pubmed">25185241</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014;124:319&#x2013;27. doi: 10.1182/blood-2013-10-532184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-10-532184</ArticleId><ArticleId IdType="pubmed">24740811</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis LB, Curtis RE, Boice JD, et al. Second cancers following non-hodgkin&#x2019;s lymphoma. Cancer. 1991;67:2002&#x2013;9. doi: 10.1002/1097-0142(19910401)67:7&lt;2002::aid-cncr2820670729&gt;3.0.co;2-e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19910401)67:7&lt;2002::aid-cncr2820670729&gt;3.0.co;2-e</ArticleId><ArticleId IdType="pubmed">2004317</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan P, Coates M, Armstrong B, et al. Second primary neoplasms following non-hodgkin&#x2019;s lymphoma in New South Wales, Australia. Br J Cancer. 2000;82:1344&#x2013;7. doi: 10.1054/bjoc.1999.1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.1999.1102</ArticleId><ArticleId IdType="pmc">PMC2374485</ArticleId><ArticleId IdType="pubmed">10755412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-hodgkin&#x2019;s lymphoma: a british Cohort Study. J Clin Oncol. 2006;24:1568&#x2013;74. doi: 10.1200/JCO.2005.04.2200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.04.2200</ArticleId><ArticleId IdType="pubmed">16520465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>